These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 23828385)

  • 21. An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma.
    Rosen G
    Cancer Treat Res; 1993; 62():49-54. PubMed ID: 8096759
    [No Abstract]   [Full Text] [Related]  

  • 22. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
    Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
    Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Organ-preserving interventions in combined therapy of children and adolescents with osteosarcoma].
    Punanov IuA; Gafton GI; Gudz' IuV; Nabokov VV; Ivanova TV; Safonova SA; Levchenko EV; Kupatadze DD; Novik VI; Lazareva IuR; Krzhivitskiĭ PI; Petrov VG
    Vopr Onkol; 2012; 58(2):275-81. PubMed ID: 22774537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
    Yu W; Tang L; Lin F; Yao Y; Shen Z
    Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults.
    Patel SJ; Lynch JW; Johnson T; Carroll RR; Schumacher C; Spanier S; Scarborough M
    Am J Clin Oncol; 2002 Oct; 25(5):489-95. PubMed ID: 12393991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
    Bacci G; Longhi A; Forni C; Fabbri N; Briccoli A; Barbieri E; Mercuri M; Balladelli A; Ferrari S; Picci P
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):505-11. PubMed ID: 17118571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
    Bacci G; Briccoli A; Rocca M; Ferrari S; Donati D; Longhi A; Bertoni F; Bacchini P; Giacomini S; Forni C; Manfrini M; Galletti S
    Ann Oncol; 2003 Jul; 14(7):1126-34. PubMed ID: 12853357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
    Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
    Cohen IJ
    Pediatr Hematol Oncol; 2003 Dec; 20(8):579-81. PubMed ID: 14578026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
    Gaspar N; Occean BV; Pacquement H; Bompas E; Bouvier C; Brisse HJ; Castex MP; Cheurfa N; Corradini N; Delaye J; Entz-Werlé N; Gentet JC; Italiano A; Lervat C; Marec-Berard P; Mascard E; Redini F; Saumet L; Schmitt C; Tabone MD; Verite-Goulard C; Le Deley MC; Piperno-Neumann S; Brugieres L; ; ;
    Eur J Cancer; 2018 Jan; 88():57-66. PubMed ID: 29190507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limb-sparing in patients with non-metastatic high-grade osteosarcoma.
    Samardziski M; Zafiroski G; Tolevska C; Zafirova-Ivanovska B; Kostadinova-Kunovska S; Kalicanin-Markovska M
    J BUON; 2009; 14(1):63-9. PubMed ID: 19373949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs.
    Fuchs N; Bielack SS; Epler D; Bieling P; Delling G; Körholz D; Graf N; Heise U; Jürgens H; Kotz R; Salzer-Kuntschik M; Weinel P; Werner M; Winkler K
    Ann Oncol; 1998 Aug; 9(8):893-9. PubMed ID: 9789613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol.
    Bacci G; Ferrari S; Longhi A; Forni C; Bertoni F; Fabbri N; Zavatta M; Versari M
    J Chemother; 2001 Feb; 13(1):93-9. PubMed ID: 11233808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma.
    Longhi A; Pignotti E; Versari M; Asta S; Bacci G
    Oncol Rep; 2003; 10(1):151-5. PubMed ID: 12469162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
    Eselgrim M; Grunert H; Kühne T; Zoubek A; Kevric M; Bürger H; Jürgens H; Mayer-Steinacker R; Gosheger G; Bielack SS
    Pediatr Blood Cancer; 2006 Jul; 47(1):42-50. PubMed ID: 16206218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
    Nataraj V; Batra A; Rastogi S; Khan SA; Sharma MC; Vishnubhatla S; Bakhshi S
    J Surg Oncol; 2015 Nov; 112(6):662-8. PubMed ID: 26381138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86).
    Winkler K; Bielack S; Delling G; Salzer-Kuntschik M; Kotz R; Greenshaw C; Jürgens H; Ritter J; Kusnierz-Glaz C; Erttmann R
    Cancer; 1990 Oct; 66(8):1703-10. PubMed ID: 2208024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
    Le Deley MC; Guinebretière JM; Gentet JC; Pacquement H; Pichon F; Marec-Bérard P; Entz-Werlé N; Schmitt C; Brugières L; Vanel D; Dupoüy N; Tabone MD; Kalifa C;
    Eur J Cancer; 2007 Mar; 43(4):752-61. PubMed ID: 17267204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial.
    Ferguson WS; Harris MB; Goorin AM; Gebhardt MC; Link MP; Shochat SJ; Siegal GP; Devidas M; Grier HE
    J Pediatr Hematol Oncol; 2001; 23(6):340-8. PubMed ID: 11563767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.